Stockreport

VYNE Therapeutics Provides Update on VYN202 Program

VYNE Therapeutics Inc.  (VYNE) 
PDF BRIDGEWATER, N.J., April 25, 2025 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that the U.S. Food and Drug Admin [Read more]